This trial is testing nivolumab with or without ipilimumab as a treatment for recurrent meningioma. Nivolumab is an immunotherapy drug that may help the body's immune system attack the cancer. Ipilimumab is also an immunotherapy drug. Stereotactic radiosurgery is a type of radiation therapy.
- Grade II Meningioma
- Grade III Meningioma
- Grade 2 Meningioma
- Grade 3 Meningioma
- Recurrent Meningiomas
4 Primary · 3 Secondary · Reporting Duration: At 6 months
Side Effects for
2 Treatment Groups
Cohort A (nivolumab, radiosurgery)
1 of 2
Cohort B (nivolumab, ipilimumab, radiosurgery)
1 of 2
38 Total Participants · 2 Treatment Groups
Primary Treatment: Stereotactic Radiosurgery · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
To what extent has Stereotactic Radiosurgery been explored in other research studies?
"At the present moment, 765 clinical trials for Stereotactic Radiosurgery are underway. Of those active studies, 86 have reached Phase 3 of clinical research. Despite Pittsburgh being a primary hub for this study, 42755 sites across the globe are offering access to these treatments." - Anonymous Online Contributor
To what extent has this research been implemented within U.S. medical practices?
"This trial is currently recruiting from 14 sites scattered throughout United States, including Miami, Los Angeles and Westwood. To reduce strain on the patient's time and budget, we encourage enrollees to choose a location close by their residence." - Anonymous Online Contributor
To what maladies has Stereotactic Radiosurgery proven most efficacious?
"Stereotactic Radiosurgery is traditionally used for the treatment of anti-angiogenic therapy, but can also be beneficial for patients with malignant neoplasms, unresectable melanoma and squamous cell carcinoma." - Anonymous Online Contributor
How many participants are involved in this research endeavor?
"For this medical study, 15 participants who meet the conditions of eligibility can take part. Those interested in enrolling have two options: The University of Miami Miller School of Medicine-Sylvester Cancer Center situated in Florida and USC / Norris Comprehensive Cancer Centre positioned in California." - Anonymous Online Contributor
Are there any openings for participants in this clinical investigation?
"According to the clinicaltrials.gov website, this research trial is actively recruiting patients. The initial posting was done on November 21st 2018 and has been recently updated as of November 15th 2022." - Anonymous Online Contributor